Whitepapers

Apr 01, 2016
Pharmaceutical Executive
How do you really know if your co-pay program is working? Figuring ROI seems straightforward. But Paul LeVine, Vice President of Analytic Services for TrialCard Market Access Solutions thinks the calculus might require a deeper look than is traditionally given as he explained at the 2nd Annual Coupon and Co-Pay Strategy Summit in Philadelphia in February.
Mar 17, 2016
Pharmaceutical Executive
Transitioning Hub programs is daunting. But making a major change can be a necessary step to foster a brand’s performance through improved patient support services. At CBI’s 6th Annual Hub and SPP Model Optimization Conference in Philadelphia this February, Scott Dulitz of Trialcard outlines key points of consideration and best practices to fast track the switch to move forward once you’ve come to the conclusion that a change is necessary.
Mar 16, 2016
Sponsored Content
The U.S. has been among the most sought-after pharmaceutical markets in the world for decades. But accessing this enormous market is not easy. Not only must entrants gain marketing approval from the Food and Drug Administration, they must also ensure access to patients by gaining prescriber and payer acceptance. Meeting the combined challenges of marketing approval, payer acceptance, assured reimbursement and access to patients is the result of a studied and deliberate approach to product development and launch. This studied approach is particularly important in rare disease product categories with low numbers of patients, high development costs and managed care plans focused on controlling spend.
Mar 10, 2016
Pharmaceutical Executive
Darryl Williams, Head of Global MDM and Platform Solutions, Health Care, for LexisNexis Risk Solutions discussed the impact of Big Data in the Life Sciences with Fierce Markets on December 8, 2015. This white paper is an expansion of the discussion exploring how and why big data will have a big impact on Life Sciences in 2016 and beyond.
Feb 23, 2016
Pharmaceutical Executive
By
Medication adherence is a broadly recognized problem that affects patients worldwide. While the magnitude of nonadherence depends on the drugs and the specific patient population, the World Health Organization reports that 50 percent of patients do not take medications as prescribed on a global basis. A novel framework that distinguishes different phases of nonadherence and promotes specific strategies that are appropriate to each phase promises to improve adherence, improve clinical outcomes and reduce overall healthcare spending.
Feb 16, 2016
Pharmaceutical Executive
From a patient perspective, hub services can often be a lifeline to managing complicated, chronic conditions. Creating a solution that supports patients who rely on “middle-ground” specialty medications is a necessity for an area that is becoming a larger part of the overall pharmaceutical landscape.
Feb 03, 2016
Pharmaceutical Executive
By
Having the right training strategy is critical to building successful collaborations with integrated customers, including ACOs and IDNs. To be successful, sales teams need to understand the strategic goals of the organization as a whole—not just the needs of providers who use their products. Download CMR Institute’s expert whitepaper to explore your customers’ enterprise-wide requirements and discover potential training gaps these needs are creating.
Jan 25, 2016
Pharmaceutical Executive
By
Payers, providers, and policy makers have become keenly interested in managing the health of specific populations, particularly those with chronic conditions who tend to be high utilizers of care. These payers and providers are designing programs that better coordinate care for high-risk patients in an effort to improve quality and reduce costs. In the following whitepaper, CMR Institute asked top executives at major ACOs and other healthcare systems for key insights and perspectives to help commercial sales teams and account managers be more successful in this new healthcare marketplace.
Jan 07, 2016
Pharmaceutical Executive
By
In this whitepaper, we offer three organizational structures — pillars on which to build a winning launch. In architecture a pillar holds the weight of the portico or roof above structural elements below. In the same way, these pillars-to-launch support practices that prioritize early planning and operational preparedness.
Jan 06, 2016
Pharmaceutical Executive
The Life Sciences industry is enduring close regulatory scrutiny, which is likely to continue to expand in scope. For Life Sciences, compliance regulations and practices such as the Physicians Payment Sunshine Act require extensive documentation related to financial and policies management as well as the data associated with these processes. There is not a one size fits all approach resulting in fragmented processes, and copious systems whose remit is to define and collect valuable data. Discover lessons learned and review solutions to ensuring valuable data collection and quality reporting.
native1_300x100
more information

www.ka4alka.com.ua
lorem ipsum